JSKN003 — Investigational Agent
Antibody-Drug Conjugate · Phase 3 · Alphamab Oncology / Shanghai JMT-Bio
Mechanism of Action
A biparatopic anti-HER2 antibody-drug conjugate carrying a topoisomerase I inhibitor payload via a glycan-conjugated, pH-sensitive linker. Dual-epitope binding enhances receptor clustering, internalization and bystander killing across HER2-positive and HER2-low tumors.
Investigational Indications
- HER2-positive metastatic breast cancer
- HER2-low metastatic breast cancer
- HER2-expressing gastric/colorectal and gynecologic cancers